JP3431300007

Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in TaiwanNxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

February 28, 2025 02:42 ET  | Source: Nxera Pharma Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin…

3 months ago
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to ViatrisNxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris

Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris

February 27, 2025 19:05 ET  | Source: Nxera Pharma Cenerimod is a novel oral S1P1 receptor modulator with potential to…

3 months ago
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with InsomniaNxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with Insomnia

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with Insomnia

December 18, 2024 21:35 ET  | Source: Nxera Pharma Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma…

5 months ago